GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for it Drug Assessment Platform
This press release can be viewed online [here]
GNQ Insilico’s quantum-enhanced, AI-powered platform to accelerate development of MindLab’s novel pain management therapy
Pleasanton, CA, United States — October 30, 2025
GNQ Insilico Inc., a pioneer in quantum-enhanced AI drug development, is pleased to announce a strategic partnership with MindLab, LLC to deploy its newly launched Drug Assessment Platform (DAP). The collaboration will support the accelerated development of MLB-001, MindLab’s lead therapeutic candidate aimed at transforming the treatment of acute pain and rare-disease conditions.
This partnership represents the first major commercial engagement for GNQ Insilico’s DAP platform and highlights the growing demand for AI-driven modeling solutions that optimize dosing, predict efficacy and safety outcomes, and strengthen regulatory readiness.
MindLab recently secured first place at the RESI Boston Conference, standing out among early-stage life-science companies. Through this collaboration, MindLab will leverage GNQ’s advanced digital-twin technology and AI-driven modeling to optimize dosing strategies, inform clinical trial design, and enhance regulatory preparedness for its next development phase.
MindLab’s proprietary next-generation pain therapeutic is designed to deliver morphine-level analgesia with approximately 50% lower opioid dosing, a longer duration of action, and reduced euphoria-driven misuse potential.
Transforming Drug Development Through Quantum-Infused Causal AI
GNQ’s Drug Assessment Platform integrates artificial intelligence, quantum computing principles, and advanced biological modeling to create digital twins that simulate drug behavior across diverse patient populations.
For MindLab’s MLB-001 program, the platform will enable:
- Accelerated development timelines by reducing preclinical testing through predictive modeling
- Enhanced safety profiling via early identification of potential safety signals
- Optimized clinical trial design through informed patient selection and dosing strategies
- Regulatory support, including FDA-aligned quantitative predictions for efficacy versus respiratory depression risk, long-term efficacy, maintenance, and physical dependence assessment
The platform’s ability to model complex drug interactions and predict individual patient responses addresses critical challenges in developing controlled substances under heightened regulatory scrutiny.
Strategic Advantages for Novel Pain Therapies
The partnership provides MindLab with several key advantages.
Regulatory Differentiation
Precision-medicine modeling supports patient-specific stratification strategies that may enhance approval prospects and differentiated labeling.
Commercial Value Creation
Insights generated may enable companion diagnostics, prescriber risk-management tools, and differentiated positioning versus standard opioid therapies.
Clinical Optimization
Real-time safety monitoring algorithms and adaptive dosing recommendations increase the probability of Phase 1 and Phase 2 trial success while minimizing patient risk.
Leadership Perspectives
“MindLab’s decision to adopt our Drug Assessment Platform validates our vision of transforming drug development through quantum-enhanced causal inference,” said Sudhir Saxena, Chief Technology Officer of GNQ Insilico. “Our digital-twin technology will give unprecedented visibility into MLB-001’s therapeutic window, enabling safer and more effective pain management solutions while accelerating development timelines.”
“Our partnership with GNQ Insilico represents a powerful convergence of neuroscience and AI,” said Larry Raoul James, JD, MBA, Founder and CEO of MindLab. “By integrating predictive modeling with our preclinical data, we are advancing a smarter, faster path to clinical validation and new options for patients living with pain.”
About MindLab Pharma, LLC
MindLab Pharma is a pharmaceutical development company focused on next-generation pain management therapies that deliver effective analgesia with improved safety and reduced abuse potential for acute and rare-disease pain conditions. Its lead program, MLB-001, uses precision combination pharmacology to achieve morphine-level pain relief at significantly lower opioid doses.
Headquarters: New York City, NY
Website: www.mindlabpharma.com
Contact: info@mindlabpharma.com
About GNQ Insilico Inc.
GNQ Insilico is a California-based TechBio company pioneering the integration of artificial intelligence, quantum computing, and advanced biological modeling in drug development. Its Drug Assessment Platform leverages digital-twin technology to predict efficacy, safety, and patient response, enabling faster development timelines and improved clinical outcomes.
Headquarters: Pleasanton, CA
Website: www.gnq.ai
Contact: info@gnq.ai